How to Help Your Patients Find Januvia in Stock: A Provider's Guide

When a patient calls your office unable to fill their Januvia prescription, the burden often lands on your care team to help resolve it. Between prior authorization appeals, pharmacy calls, and savings card lookups, these access issues consume clinical staff time that could be better spent on patient care. This guide gives you a practical, efficient workflow for helping patients find and access Januvia — or a suitable alternative — as quickly as possible.

Step 1: Identify the Actual Barrier

When a patient reports they can't get their Januvia, the first step is identifying why. The solution varies significantly depending on the root cause:

Pharmacy doesn't have it in stock: Redirect to a larger chain pharmacy or use medfinder to locate stock nearby

Insurance denied or requires prior authorization: Initiate PA request with supporting clinical documentation

Too expensive even with insurance: Connect patient with Merck savings card or patient assistance program

Uninsured or Medicare/Medicaid patient: Apply for Merck Patient Assistance Program or discuss generic alternatives

Step 2: Use medfinder to Find In-Stock Pharmacies

Rather than having your staff call multiple pharmacies one by one, medfinder for Providers automates the pharmacy search process. Your team enters the patient's medication (Januvia, dose, quantity) and location, and medfinder calls pharmacies to find which ones can fill the prescription. Results are delivered quickly, eliminating the need for manual pharmacy calling.

This is particularly useful when:

The patient's usual pharmacy doesn't stock the specific Januvia dose they need (25 mg or 50 mg are less commonly stocked than 100 mg)

The patient has limited mobility and can't easily visit multiple pharmacies

The patient is elderly or non-English-speaking and needs your team's assistance navigating the process

Step 3: Connect Patients With Cost-Saving Resources

Keep these resources readily available in your practice:

Merck Savings Card (januvia.com): For commercially insured patients; as low as $5/fill, up to $150 off per prescription. Not valid for government insurance programs.

Merck Patient Assistance Program (merckhelps.com / 1-800-727-5400): For uninsured/underinsured patients meeting income criteria; provides Januvia free of charge for up to 1 year with reapplication allowed.

GoodRx / SingleCare discount cards: Can reduce Januvia to $285–$350/month; generic sitagliptin (Zituvio/authorized) as low as $110 with GoodRx at select pharmacies.

Merck samples (Merck Sample Portal): Request practice samples to bridge patients while PA decisions are pending or while assistance program paperwork is processed.

Step 4: Navigating Prior Authorization Efficiently

If the patient's insurance requires a PA, your team should submit one promptly rather than switching therapy unnecessarily. Key elements to include in the PA request:

Confirmed diagnosis of type 2 diabetes (not type 1)

Documentation of metformin trial: dates, dose, duration, reason for inadequate response or intolerance

Most recent HbA1c value and treatment goal

Current eGFR (relevant to clinical decision-making and dose selection)

Rationale for DPP-4 class: low hypoglycemia risk, weight neutrality, once-daily oral administration, good tolerability profile

Any contraindications to lower-tier agents (e.g., heart failure history precluding saxagliptin or alogliptin)

Step 5: When to Consider Switching — and What to Switch To

If Januvia access remains consistently difficult or cost-prohibitive despite assistance programs, a therapeutic switch may be the most practical path. Consider these options based on patient profile:

eGFR <45 with good adherence on DPP-4: Switch to Tradjenta (linagliptin) — no dose adjustment needed

Cost is primary concern, no HF history: Switch to generic saxagliptin or alogliptin

Established ASCVD, HF, or CKD with albuminuria: Per ADA guidelines, consider SGLT2 inhibitor (empagliflozin, dapagliflozin) or GLP-1 agonist

Patient specifically needs sitagliptin: Write new Rx for Zituvio (sitagliptin free base) — same active ingredient, potentially cheaper

Preparing Your Practice for Generic Sitagliptin Entry

Generic sitagliptin phosphate is expected to enter the market in 2026, following patent expiry on November 24, 2026 and potential early entry under settlement agreements from May 2026. Advise your staff to:

Monitor formulary updates from major insurance plans for when generic sitagliptin achieves Tier 1-2 coverage

Prepare to update prescription templates if "sitagliptin" (generic) can now be prescribed directly rather than "Januvia" (brand)

Notify patients currently struggling with Januvia cost that relief may be coming later in 2026

For a clinical overview of Januvia access from a prescriber perspective, see: Januvia Shortage: What Providers and Prescribers Need to Know in 2026.